Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

医学 曲妥珠单抗 肿瘤科 结直肠癌 内科学 临床终点 队列 中期分析 化疗 瑞戈非尼 癌症 临床试验 乳腺癌
作者
John H. Strickler,Andrea Cercek,Salvatore Siena,Thierry André,Kimmie Ng,Eric Van Cutsem,Christina Wu,Andrew Scott Paulson,Joleen M. Hubbard,Andrew L. Coveler,Christos Fountzilas,Adel Kardosh,Pashtoon Murtaza Kasi,Heinz‐Josef Lenz,Kristen K. Ciombor,Elena Élez,David L. Bajor,Chiara Cremolini,Federico Sanchez,Michael Stecher
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:24 (5): 496-508 被引量:142
标识
DOI:10.1016/s1470-2045(23)00150-x
摘要

Summary

Background

HER2 is an actionable target in metastatic colorectal cancer. We assessed the activity of tucatinib plus trastuzumab in patients with chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer.

Methods

MOUNTAINEER is a global, open-label, phase 2 study that enrolled patients aged 18 years and older with chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer at 34 sites (clinics and hospitals) in five countries (Belgium, France, Italy, Spain, and the USA). Initially, the study was designed as a single-cohort study, which was expanded following an interim analysis to include more patients. Initially, patients were given tucatinib (300 mg orally twice daily) plus intravenous trastuzumab (8 mg/kg as an initial loading dose, then 6 mg/kg every 21 days; cohort A) for the duration of treatment (until progression), and after expansion, patients were randomly assigned (4:3), using an interactive web response system and stratified by primary tumour location, to either tucatinib plus trastuzumab (cohort B) or tucatinib monotherapy (cohort C). The primary endpoint was confirmed objective response rate per blinded independent central review (BICR) for cohorts A and B combined and was assessed in patients in the full analysis set (ie, patients with HER2-positive disease who received at least one dose of study treatment). Safety was assessed in all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, NCT03043313, and is ongoing.

Findings

Between Aug 8, 2017, and Sept 22, 2021, 117 patients were enrolled (45 in cohort A, 41 in cohort B, and 31 in cohort C), of whom 114 patients had locally assessed HER2-positive disease and received treatment (45 in cohort A, 39 in cohort B, and 30 in cohort C; full analysis set), and 116 patients received at least one dose of study treatment (45 in cohort A, 41 in cohort B, and 30 in cohort C; safety population). In the full analysis set, median age was 56·0 years (IQR 47–64), 66 (58%) were male, 48 (42%) were female, 88 (77%) were White, and six (5%) were Black or African American. As of data cutoff (March 28, 2022), in 84 patients from cohorts A and B in the full analysis set, the confirmed objective response rate per BICR was 38·1% (95% CI 27·7–49·3; three patients had a complete response and 29 had a partial response). In cohorts A and B, the most common adverse event was diarrhoea (55 [64%] of 86), the most common grade 3 or worse adverse event was hypertension (six [7%] of 86), and three (3%) patients had tucatinib-related serious adverse events (acute kidney injury, colitis, and fatigue). In cohort C, the most common adverse event was diarrhoea (ten [33%] of 30), the most common grade 3 or worse adverse events were increased alanine aminotransferase and aspartate aminotransferase (both two [7%]), and one (3%) patient had a tucatinib-related serious adverse event (overdose). No deaths were attributed to adverse events. All deaths in treated patients were due to disease progression.

Interpretation

Tucatinib plus trastuzumab had clinically meaningful anti-tumour activity and favourable tolerability. This treatment is the first US Food and Drug Administration-approved anti-HER2 regimen for metastatic colorectal cancer and is an important new treatment option for chemotherapy-refractory HER2-positive metastatic colorectal cancer.

Funding

Seagen and Merck & Co.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
朱成豪发布了新的文献求助10
1秒前
deallyxyz应助科研通管家采纳,获得10
1秒前
科目三应助科研通管家采纳,获得10
1秒前
大个应助科研通管家采纳,获得10
1秒前
比比谁的速度快应助曾珍采纳,获得50
1秒前
1秒前
予修应助科研通管家采纳,获得10
1秒前
搜集达人应助科研通管家采纳,获得10
1秒前
wanci应助科研通管家采纳,获得30
1秒前
1秒前
1秒前
吹雪完成签到,获得积分0
1秒前
美好的尔白完成签到,获得积分10
1秒前
O-M175完成签到,获得积分10
2秒前
Jasper应助hahaha123213123采纳,获得10
2秒前
可爱的函函应助天天向上采纳,获得10
3秒前
陈隆完成签到,获得积分10
7秒前
7秒前
高乾飞完成签到 ,获得积分10
8秒前
河大青椒完成签到,获得积分10
8秒前
丘比特应助动听的秋白采纳,获得10
9秒前
晒黑的雪碧完成签到,获得积分10
10秒前
yao chen完成签到,获得积分10
11秒前
catch完成签到,获得积分10
11秒前
Hrx完成签到,获得积分10
11秒前
哎呀哎呀25完成签到,获得积分10
12秒前
15秒前
Shark完成签到 ,获得积分10
15秒前
我要发财完成签到,获得积分10
16秒前
卡卡罗特完成签到,获得积分10
16秒前
16秒前
天天向上完成签到 ,获得积分10
17秒前
Xinxxx完成签到,获得积分10
17秒前
Echoheart完成签到,获得积分10
17秒前
Hrx发布了新的文献求助10
18秒前
我要发财发布了新的文献求助10
20秒前
WJing发布了新的文献求助10
21秒前
haonanchen完成签到,获得积分10
22秒前
彭于晏应助专注的白柏采纳,获得10
22秒前
99v587完成签到,获得积分10
23秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029